BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1242 related articles for article (PubMed ID: 17049692)

  • 1. Booster immunization with a hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus vaccine and Haemophilus influenzae type b conjugate combination vaccine in the second year of life: safety, immunogenicity and persistence of antibody responses.
    Heininger U; ; ; Sänger R; Jacquet JM; Schuerman L
    Vaccine; 2007 Jan; 25(6):1055-63. PubMed ID: 17049692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity and reactogenicity of two regimens of diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio and Haemophilus influenzae type b vaccines administered to infants primed at birth with hepatitis B vaccine.
    Cheng HK; Rajadurai VS; Amin Z; Sriram B; Yee MF; Han HH; Bock HL; Safary A
    Southeast Asian J Trop Med Public Health; 2004 Sep; 35(3):685-92. PubMed ID: 15689088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity, reactogenicity and safety of a 7-valent pneumococcal conjugate vaccine (PCV7) concurrently administered with a DTPa-HBV-IPV/Hib combination vaccine in healthy infants.
    Knuf M; Habermehl P; Cimino C; Petersen G; Schmitt HJ
    Vaccine; 2006 May; 24(22):4727-36. PubMed ID: 16616973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity and reactogenicity of primary immunization with a hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type B vaccine coadministered with two doses of a meningococcal C-tetanus toxoid conjugate vaccine.
    Tejedor JC; Moro M; Ruiz-Contreras J; Castro J; Gómez-Campderá JA; Navarro ML; Merino JM; Martín-Ancel A; Roca J; García-del-Río M; Jurado A; Díez-Delgado FJ; Omeñaca F; García-Sicilia J; Boceta R; García-Corbeira P; Jacquet JM; Collard A; Schuerman L;
    Pediatr Infect Dis J; 2006 Aug; 25(8):713-20. PubMed ID: 16874171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody persistence, PRP-specific immune memory, and booster responses in infants immunised with a combination DTPa-HBV-IPV/Hib vaccine.
    Nolan T; Altmann A; Skeljo M; Streeton C; Schuerman L
    Vaccine; 2004 Nov; 23(1):14-20. PubMed ID: 15519702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity, reactogenicity, and safety of a seven-valent pneumococcal conjugate vaccine (PCV7) concurrently administered with a fully liquid DTPa-IPV-HBV-Hib combination vaccine in healthy infants.
    Olivier C; Belohradsky BH; Stojanov S; Bonnet E; Petersen G; Liese JG
    Vaccine; 2008 Jun; 26(25):3142-52. PubMed ID: 18502545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Booster vaccination with hexavalent DTPa-HBV-IPV/Hib vaccine in the second year of life is as safe as concomitant DTPa-IPV/Hib + HBV administered separately.
    Saenger R; Maechler G; Potreck M; Zepp F; Knuf M; Habermehl P; Schuerman L
    Vaccine; 2005 Jan; 23(9):1135-43. PubMed ID: 15629356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety, reactogenicity and immunogenicity of a combined hexavalent tetanus, diphtheria, acellular pertussis, hepatitis B, inactivated poliovirus vaccine and Haemophilus influenzae type b conjugate vaccine, for primary immunization of infants.
    Zepp F; Knuf M; Heininger U; Jahn K; Collard A; Habermehl P; Schuerman L; Sänger R
    Vaccine; 2004 Jun; 22(17-18):2226-33. PubMed ID: 15149781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary and booster immunization with a diphtheria, tetanus, acellular pertussis, hepatitis B (DTPa-HBV) and Haemophilus influenzae type b (Hib) vaccine administered separately or together is safe and immunogenic.
    Marshall H; McIntyre P; Roberton D; Dinan L; Hardt K
    Int J Infect Dis; 2010 Jan; 14(1):e41-9. PubMed ID: 19467896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and immunogenicity of a primary course and booster dose of a combined diphtheria, tetanus, acellular pertussis, hepatitis B and inactivated poliovirus vaccine.
    Meriste S; Lutsar I; Tamm E; Willems P
    Scand J Infect Dis; 2006; 38(5):350-6. PubMed ID: 16709537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reactogenicity and immunogenicity profiles of a novel pentavalent diphtheria-tetanus-whole cell pertussis-hepatitis B and Haemophilus influenzae type B vaccine: a randomized dose-ranging trial of the Hib tetanus-conjugate content.
    Hla KH; Thein SA; Aye A; Han HH; Bock HL; David MP; Schuerman L
    Pediatr Infect Dis J; 2006 Aug; 25(8):706-12. PubMed ID: 16874170
    [TBL] [Abstract][Full Text] [Related]  

  • 12. One-year post-primary antibody persistence and booster immune response to a fully liquid five-component acellular pertussis, diphtheria, tetanus, inactivated poliomyelitis, Haemophilus influenzae type b conjugate vaccine.
    Lin TY; Wang YH; Huang YC; Chiu CH; Lin PY; Chen CJ; Chavand P; Ortiz E
    Int J Infect Dis; 2007 Nov; 11(6):488-95. PubMed ID: 17349809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity and safety of a DTaP-IPV//PRP-T vaccine (Pentaxim) booster during the second year of life in Thai children primed with an acellular pertussis combined vaccine.
    Thisyakorn U; Pancharoen C; Chuenkitmongkol S; Ortiz E
    Southeast Asian J Trop Med Public Health; 2009 Mar; 40(2):282-94. PubMed ID: 19323013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and safety following primary and booster vaccination with a hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus and Haemophilus influenzae type b vaccine: a randomized trial in the United States.
    Klein NP; Abu-Elyazeed R; Cheuvart B; Janssens W; Mesaros N
    Hum Vaccin Immunother; 2019; 15(4):809-821. PubMed ID: 30444673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and immunogenicity of a toddler dose following an infant series of a hexavalent diphtheria, tetanus, acellular pertussis, inactivated poliovirus, Haemophilus influenzae type b, hepatitis B vaccine administered concurrently or at separate visits with a heptavalent pneumococcal conjugate vaccine.
    Halperin SA; Tapiéro B; Dionne M; Meekison W; Diaz-Mitoma F; Zickler P; Rubin E; Embree J; Bhuyan P; Lee A; Li M; Tomovici A
    Pediatr Infect Dis J; 2014 Jan; 33(1):73-80. PubMed ID: 24346596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity and safety of primary and booster vaccination with 2 investigational formulations of diphtheria, tetanus and Haemophilus influenzae type b antigens in a hexavalent DTPa-HBV-IPV/Hib combination vaccine in comparison with the licensed Infanrix hexa.
    Vesikari T; Rivera L; Korhonen T; Ahonen A; Cheuvart B; Hezareh M; Janssens W; Mesaros N
    Hum Vaccin Immunother; 2017 Jul; 13(7):1505-1515. PubMed ID: 28340322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunological persistence in 5 y olds previously vaccinated with hexavalent DTPa-HBV-IPV/Hib at 3, 5, and 11 months of age.
    Silfverdal SA; Assudani D; Kuriyakose S; Van Der Meeren O
    Hum Vaccin Immunother; 2014; 10(10):2795-8. PubMed ID: 25483640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity and reactogenicity of a three-dose primary vaccination course with a combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-haemophilus influenzae type b vaccine coadministered with a meningococcal C conjugate vaccine.
    Tejedor JC; Omeñaca F; García-Sicilia J; Verdaguer J; Van Esso D; Esporrín C; Molina V; Muro M; Marés J; Enrubia M; Moraga F; García-Corbeira P; Dobbelaere K; Schuerman L;
    Pediatr Infect Dis J; 2004 Dec; 23(12):1109-15. PubMed ID: 15626947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and immunogenicity of a hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine at 2, 3, 4, and 12-14 months of age.
    Halperin SA; Tapiero B; Diaz-Mitoma F; Law BJ; Hoffenbach A; Zappacosta PS; Radley D; McCarson BJ; Martin JC; Brackett LE; Boslego JW; Hesley TM; Bhuyan PK; Silber JL
    Vaccine; 2009 Apr; 27(19):2540-7. PubMed ID: 19124057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lasting immune memory against hepatitis B following challenge 10-11 years after primary vaccination with either three doses of hexavalent DTPa-HBV-IPV/Hib or monovalent hepatitis B vaccine at 3, 5 and 11-12 months of age.
    Avdicova M; Crasta PD; Hardt K; Kovac M
    Vaccine; 2015 May; 33(23):2727-33. PubMed ID: 24962750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 63.